DRMA - Latest News
Dermata Therapeutics, Inc. (DRMA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $913,286. Beta to the broader market is 0.66.
The article list below shows the most recent DRMA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent DRMA Headlines
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
accessnewswire.com - Aug 25, 2026
- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www. tomeskincare.
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
accessnewswire.com - Aug 21, 2026
- Preorders can be made by visiting www. tomeskincare.
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
accessnewswire.com - Aug 17, 2026
$3. 4 million upfront with up to approximately $6.
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
accessnewswire.com - Aug 11, 2026
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently at
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
accessnewswire.com - Aug 5, 2026
- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch, planned for August 25, 2026 - - Join the waitlist
How News Affects DRMA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track DRMA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked DRMA news questions
- What is the latest DRMA news headline?
- The most recent DRMA headline (Aug 25, 2026) is "Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the DRMA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What DRMA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual DRMA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.